Vestagen rejigs top brass, eyes protective apparel market
July 22, 2015 - United States Of America
Orlando-based Vestagen Technical Textiles, Inc., a leader in the provision of technology-based protective attire for healthcare and other applications has announced a number of additions and changes to its leadership team.
Barbara DeBaun, RN, MSN, CIC, has been named consulting vice president of clinical affairs, Stewart B. Davis MD, has been named consulting vice president of regulatory and medical affairs, and Marc Lessem has joined as chief marketing officer and senior vice president of sales and marketing. Executive chairman Dale Pfost, PhD, has assumed the additional role of chief executive officer and Vestagen founder Uncas “Ben” B. Favret lll has been named president, the company said in a statement.
Vestagen’s Vestex, the first in a new class of active barrier technologies that combines fluid repellent, antimicrobial and breathability properties, is the only daily-use fabric proven in a hospital setting to reduce harmful contaminants on garments, the statement said.
Vestex protective uniforms are designed to increase healthcare worker and patient safety by reducing the risk that dangerous pathogens and other contaminants will be spread by workers’ attire.
“The calibre of our new hires is a testament to the potential of Vestex technology to transform healthcare uniforms from a possible hazard into an essential part of the evidence-based infection control measures hospitals are adopting to achieve a culture of safety,” said Dr. Pfost. “Barbara DeBaun’s national reputation from her three decades as a highly respected expert in quality improvement, infection prevention and patient safety will be tremendously valuable in our campaign to show how Vestex can support strategic initiatives to improve worker and patient safety, engagement and satisfaction.”
“Dr. Davis’ broad expertise in managing the development of novel medical devices will be very helpful as we generate additional clinical and regulatory support for Vestex,” Pfost added. “Building on the early success of the first system-wide adoption of Vestex garments at Jacksonville’s Baptist Health, Marc Lessem’s deep experience in overseeing the sales of novel products to healthcare institutions worldwide should enable us to develop the highly effective sales and marketing organization needed to grow the company to the next stage.”
Vestagen claims that Vestex is clinically proven to prevent or reduce the acquisition and retention of contaminants on clothing, reducing methicillin-resistant Staphylococcus aureus (MRSA) on the fabric by 99.99 per cent compared to traditional uniforms.(SH)
Barbara DeBaun, RN, MSN, CIC, has been named consulting vice president of clinical affairs, Stewart B. Davis MD, has been named consulting vice president of regulatory and medical affairs, and Marc Lessem has joined as chief marketing officer and senior vice president of sales and marketing. Executive chairman Dale Pfost, PhD, has assumed the additional role of chief executive officer and Vestagen founder Uncas “Ben” B. Favret lll has been named president, the company said in a statement.
Vestagen’s Vestex, the first in a new class of active barrier technologies that combines fluid repellent, antimicrobial and breathability properties, is the only daily-use fabric proven in a hospital setting to reduce harmful contaminants on garments, the statement said.
Vestex protective uniforms are designed to increase healthcare worker and patient safety by reducing the risk that dangerous pathogens and other contaminants will be spread by workers’ attire.
“The calibre of our new hires is a testament to the potential of Vestex technology to transform healthcare uniforms from a possible hazard into an essential part of the evidence-based infection control measures hospitals are adopting to achieve a culture of safety,” said Dr. Pfost. “Barbara DeBaun’s national reputation from her three decades as a highly respected expert in quality improvement, infection prevention and patient safety will be tremendously valuable in our campaign to show how Vestex can support strategic initiatives to improve worker and patient safety, engagement and satisfaction.”
“Dr. Davis’ broad expertise in managing the development of novel medical devices will be very helpful as we generate additional clinical and regulatory support for Vestex,” Pfost added. “Building on the early success of the first system-wide adoption of Vestex garments at Jacksonville’s Baptist Health, Marc Lessem’s deep experience in overseeing the sales of novel products to healthcare institutions worldwide should enable us to develop the highly effective sales and marketing organization needed to grow the company to the next stage.”
Vestagen claims that Vestex is clinically proven to prevent or reduce the acquisition and retention of contaminants on clothing, reducing methicillin-resistant Staphylococcus aureus (MRSA) on the fabric by 99.99 per cent compared to traditional uniforms.(SH)